JPRN-jRCTs031210183
Completed
未知
Exploratory research for consideration of virus inhibitory effect, safety and optimal dose of nafamostat mesilate in early mild COVID-19 patients
Okugawa Shu0 sites30 target enrollmentJuly 5, 2021
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Coronavirus Disease 2019(COVID-19)
- Sponsor
- Okugawa Shu
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\)Patients who have given written consent to participate in the study
- •2\)SARS\-CoV\-2 PCR Positive
- •3\) Patients in need of inpatient treatment
- •4\)Patents with no obvious pneumonia on chest images
- •5\)Patients who are hospitalized and can start study drug administration within 5days after the onset of COVID\-19 symptoms
Exclusion Criteria
- •1\)Patients with recurrence or reinfection of COVID\-19
- •2\) Patients who are asymptomatic or whose onset date of various symptoms due to COVID\-19 cannot be specified
- •3\) Patients suspected of having infection with microorganisms other than SARS\-CoV\-2 requiring treatment
- •4\) Patients with hyperkalemia or hyponatremia
- •5\) Patients undergoing or planning treatment for malignant tumors
- •6\) Patients with severe liver dysfunction or renal dysfunction requiring dialysis
- •7\) Patients with impaired consciousness such as disorientation
- •8\)Patients who are pregnant or who may be pregnant
- •9\) Patients with weakened immune system
- •10\)Patients with a history of hypersensitivity to Nafamostat Mesilate
Outcomes
Primary Outcomes
Not specified
Similar Trials
Unknown
Not Applicable
Study of factors of virus and host sassociated with severe Enterovirus diseasesEnterovirus71 infectionJPRN-UMIN000023742Tokyo Metropolitan Children's Medical Center100
Enrolling By Invitation
Not Applicable
Study on the Evaluation of the Infectious Process of SARS-CoV-2 in Teachers and Students in Saxony (COVID-19)infection and antibody status for Sars-CoV-2COVID-19DRKS00022032niversität Leipzig4,000
Not yet recruiting
Not Applicable
Otitis Media Infectious Aetiology & Vaccine Impact StudyACTRN12611000383965Starship Children's Hospital - ADHB300
Completed
Phase 1
Infectivity of the Plasmodium falciparum NF54 malaria cell bank, MCB-002, in humansACTRN12612001153808Griffith University2
Completed
Phase 1
Infectivity of the Plasmodium falciparum 7G8 malaria cell bank, MCB-004, in humans.ACTRN12613001187730Griffith University2